PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma

Xiaochao Tan; Priyam Banerjee; Edward A. Pham; Florentine U.N. Rutaganira; Kaustabh Basu; Neus Bota-Rabassedas; Hou Fu Guo; Caitlin L. Grzeskowiak; Xin Liu; Jiang Yu; Lei Shi; David H. Peng; B. Leticia Rodriguez; Jiaqi Zhang; Veronica Zheng; Dzifa Y. Duose; Luisa M. Solis; Barbara Mino; Maria Gabriela Raso; Carmen Behrens; Ignacio I. Wistuba; Kenneth L. Scott; Mark Smith; Khanh Nguyen; Grace Lam; Ingrid Choong; Abhijit Mazumdar; Jamal L. Hill; Don L. Gibbons; Powel H. Brown; William K. Russell; Kevan Shokat; Chad J. Creighton; Jeffrey S. Glenn; Jonathan M. Kurie

doi:10.1126/scitranslmed.aax3772

PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma

Xiaochao Tan, Priyam Banerjee, Edward A. Pham, Florentine U.N. Rutaganira, Kaustabh Basu, Neus Bota-Rabassedas, Hou Fu Guo, Caitlin L. Grzeskowiak, Xin Liu, Jiang Yu, Lei Shi, David H. Peng, B. Leticia Rodriguez, Jiaqi Zhang, Veronica Zheng, Dzifa Y. Duose, Luisa M. Solis, Barbara Mino, Maria Gabriela Raso, Carmen BehrensIgnacio I. Wistuba, Kenneth L. Scott, Mark Smith, Khanh Nguyen, Grace Lam, Ingrid Choong, Abhijit Mazumdar, Jamal L. Hill, Don L. Gibbons, Powel H. Brown, William K. Russell, Kevan Shokat, Chad J. Creighton, Jeffrey S. Glenn, Jonathan M. Kurie

Research output: Contribution to journal › Article › peer-review

24 Citations (SciVal)

Abstract

Heightened secretion of protumorigenic effector proteins is a feature of malignant cells. Yet, the molecular underpinnings and therapeutic implications of this feature remain unclear. Here, we identify a chromosome 1q region that is frequently amplified in diverse cancer types and encodes multiple regulators of secretory vesicle biogenesis and trafficking, including the Golgi-dedicated enzyme phosphatidylinositol (PI)-4-kinase IIIβ (PI4KIIIβ). Molecular, biochemical, and cell biological studies show that PI4KIIIβ-derived PI-4-phosphate (PI4P) synthesis enhances secretion and accelerates lung adenocarcinoma progression by activating Golgi phosphoprotein 3 (GOLPH3)-dependent vesicular release from the Golgi. PI4KIIIβ-dependent secreted factors maintain 1q-amplified cancer cell survival and influence prometastatic processes in the tumor microenvironment. Disruption of this functional circuitry in 1q-amplified cancer cells with selective PI4KIIIβ antagonists induces apoptosis and suppresses tumor growth and metastasis. These results support a model in which chromosome 1q amplifications create a dependency on PI4KIIIβ-dependent secretion for cancer cell survival and tumor progression.

Original language	English
Article number	eaax3772
Journal	Science Translational Medicine
Volume	12
Issue number	527
DOIs	https://doi.org/10.1126/scitranslmed.aax3772
State	Published - Jan 22 2020

Bibliographical note

Funding Information:
This work was supported by the NIH through R01 CA181184 (to J.M.K.), R01 CA2111125 (to J.M.K.), R01AI099245 (to J.S.G.), U19AI109662 (to J.S.G.), P30 CA125123 (to C.J.C.), K99 CA225633 (to H.-F.G.), NIH Lung Cancer SPORE grant P50 CA70907 (to J.M.K. and I.I.W.), Lung Cancer Research Foundation FP#00005299 (to X.T.), and Department of Defense PROSPECT grant W81XWH-07-1-0306 (to I.I.W.). NCI P30 CA16672 Core grant supported flow cytometry. This work was funded by CPRIT-MIRA RP160652. J.M.K. holds the Elza A. and Ina S. Freeman Endowed Professorship in Lung Cancer. D.H.P. was supported by a CPRIT Graduate Scholar Training Grant (RP140106). D.L.G. is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeanne F Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. E.A.P. is supported by the Stanford ChEM-H Physician Scientist Research Fellowship.

Publisher Copyright:
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

ASJC Scopus subject areas

Medicine (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1126/scitranslmed.aax3772

Cite this

Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U. N., Basu, K., Bota-Rabassedas, N., Guo, H. F., Grzeskowiak, C. L., Liu, X., Yu, J., Shi, L., Peng, D. H., Leticia Rodriguez, B., Zhang, J., Zheng, V., Duose, D. Y., Solis, L. M., Mino, B., Raso, M. G., ... Kurie, J. M. (2020). PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma. Science Translational Medicine, 12(527), [eaax3772]. https://doi.org/10.1126/scitranslmed.aax3772

@article{7adc9590e28f4f6d818a2fcc829c8853,

title = "PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma",

abstract = "Heightened secretion of protumorigenic effector proteins is a feature of malignant cells. Yet, the molecular underpinnings and therapeutic implications of this feature remain unclear. Here, we identify a chromosome 1q region that is frequently amplified in diverse cancer types and encodes multiple regulators of secretory vesicle biogenesis and trafficking, including the Golgi-dedicated enzyme phosphatidylinositol (PI)-4-kinase IIIβ (PI4KIIIβ). Molecular, biochemical, and cell biological studies show that PI4KIIIβ-derived PI-4-phosphate (PI4P) synthesis enhances secretion and accelerates lung adenocarcinoma progression by activating Golgi phosphoprotein 3 (GOLPH3)-dependent vesicular release from the Golgi. PI4KIIIβ-dependent secreted factors maintain 1q-amplified cancer cell survival and influence prometastatic processes in the tumor microenvironment. Disruption of this functional circuitry in 1q-amplified cancer cells with selective PI4KIIIβ antagonists induces apoptosis and suppresses tumor growth and metastasis. These results support a model in which chromosome 1q amplifications create a dependency on PI4KIIIβ-dependent secretion for cancer cell survival and tumor progression.",

author = "Xiaochao Tan and Priyam Banerjee and Pham, {Edward A.} and Rutaganira, {Florentine U.N.} and Kaustabh Basu and Neus Bota-Rabassedas and Guo, {Hou Fu} and Grzeskowiak, {Caitlin L.} and Xin Liu and Jiang Yu and Lei Shi and Peng, {David H.} and {Leticia Rodriguez}, B. and Jiaqi Zhang and Veronica Zheng and Duose, {Dzifa Y.} and Solis, {Luisa M.} and Barbara Mino and Raso, {Maria Gabriela} and Carmen Behrens and Wistuba, {Ignacio I.} and Scott, {Kenneth L.} and Mark Smith and Khanh Nguyen and Grace Lam and Ingrid Choong and Abhijit Mazumdar and Hill, {Jamal L.} and Gibbons, {Don L.} and Brown, {Powel H.} and Russell, {William K.} and Kevan Shokat and Creighton, {Chad J.} and Glenn, {Jeffrey S.} and Kurie, {Jonathan M.}",

note = "Funding Information: This work was supported by the NIH through R01 CA181184 (to J.M.K.), R01 CA2111125 (to J.M.K.), R01AI099245 (to J.S.G.), U19AI109662 (to J.S.G.), P30 CA125123 (to C.J.C.), K99 CA225633 (to H.-F.G.), NIH Lung Cancer SPORE grant P50 CA70907 (to J.M.K. and I.I.W.), Lung Cancer Research Foundation FP#00005299 (to X.T.), and Department of Defense PROSPECT grant W81XWH-07-1-0306 (to I.I.W.). NCI P30 CA16672 Core grant supported flow cytometry. This work was funded by CPRIT-MIRA RP160652. J.M.K. holds the Elza A. and Ina S. Freeman Endowed Professorship in Lung Cancer. D.H.P. was supported by a CPRIT Graduate Scholar Training Grant (RP140106). D.L.G. is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeanne F Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. E.A.P. is supported by the Stanford ChEM-H Physician Scientist Research Fellowship. Publisher Copyright: Copyright {\textcopyright} 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works",

year = "2020",

month = jan,

day = "22",

doi = "10.1126/scitranslmed.aax3772",

language = "English",

volume = "12",

number = "527",

}

Tan, X, Banerjee, P, Pham, EA, Rutaganira, FUN, Basu, K, Bota-Rabassedas, N, Guo, HF, Grzeskowiak, CL, Liu, X, Yu, J, Shi, L, Peng, DH, Leticia Rodriguez, B, Zhang, J, Zheng, V, Duose, DY, Solis, LM, Mino, B, Raso, MG, Behrens, C, Wistuba, II, Scott, KL, Smith, M, Nguyen, K, Lam, G, Choong, I, Mazumdar, A, Hill, JL, Gibbons, DL, Brown, PH, Russell, WK, Shokat, K, Creighton, CJ, Glenn, JS & Kurie, JM 2020, 'PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma', Science Translational Medicine, vol. 12, no. 527, eaax3772. https://doi.org/10.1126/scitranslmed.aax3772

TY - JOUR

T1 - PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma

AU - Tan, Xiaochao

AU - Banerjee, Priyam

AU - Pham, Edward A.

AU - Rutaganira, Florentine U.N.

AU - Basu, Kaustabh

AU - Bota-Rabassedas, Neus

AU - Guo, Hou Fu

AU - Grzeskowiak, Caitlin L.

AU - Liu, Xin

AU - Yu, Jiang

AU - Shi, Lei

AU - Peng, David H.

AU - Leticia Rodriguez, B.

AU - Zhang, Jiaqi

AU - Zheng, Veronica

AU - Duose, Dzifa Y.

AU - Solis, Luisa M.

AU - Mino, Barbara

AU - Raso, Maria Gabriela

AU - Behrens, Carmen

AU - Wistuba, Ignacio I.

AU - Scott, Kenneth L.

AU - Smith, Mark

AU - Nguyen, Khanh

AU - Lam, Grace

AU - Choong, Ingrid

AU - Mazumdar, Abhijit

AU - Hill, Jamal L.

AU - Gibbons, Don L.

AU - Brown, Powel H.

AU - Russell, William K.

AU - Shokat, Kevan

AU - Creighton, Chad J.

AU - Glenn, Jeffrey S.

AU - Kurie, Jonathan M.

N1 - Funding Information: This work was supported by the NIH through R01 CA181184 (to J.M.K.), R01 CA2111125 (to J.M.K.), R01AI099245 (to J.S.G.), U19AI109662 (to J.S.G.), P30 CA125123 (to C.J.C.), K99 CA225633 (to H.-F.G.), NIH Lung Cancer SPORE grant P50 CA70907 (to J.M.K. and I.I.W.), Lung Cancer Research Foundation FP#00005299 (to X.T.), and Department of Defense PROSPECT grant W81XWH-07-1-0306 (to I.I.W.). NCI P30 CA16672 Core grant supported flow cytometry. This work was funded by CPRIT-MIRA RP160652. J.M.K. holds the Elza A. and Ina S. Freeman Endowed Professorship in Lung Cancer. D.H.P. was supported by a CPRIT Graduate Scholar Training Grant (RP140106). D.L.G. is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeanne F Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. E.A.P. is supported by the Stanford ChEM-H Physician Scientist Research Fellowship. Publisher Copyright: Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

PY - 2020/1/22

Y1 - 2020/1/22

N2 - Heightened secretion of protumorigenic effector proteins is a feature of malignant cells. Yet, the molecular underpinnings and therapeutic implications of this feature remain unclear. Here, we identify a chromosome 1q region that is frequently amplified in diverse cancer types and encodes multiple regulators of secretory vesicle biogenesis and trafficking, including the Golgi-dedicated enzyme phosphatidylinositol (PI)-4-kinase IIIβ (PI4KIIIβ). Molecular, biochemical, and cell biological studies show that PI4KIIIβ-derived PI-4-phosphate (PI4P) synthesis enhances secretion and accelerates lung adenocarcinoma progression by activating Golgi phosphoprotein 3 (GOLPH3)-dependent vesicular release from the Golgi. PI4KIIIβ-dependent secreted factors maintain 1q-amplified cancer cell survival and influence prometastatic processes in the tumor microenvironment. Disruption of this functional circuitry in 1q-amplified cancer cells with selective PI4KIIIβ antagonists induces apoptosis and suppresses tumor growth and metastasis. These results support a model in which chromosome 1q amplifications create a dependency on PI4KIIIβ-dependent secretion for cancer cell survival and tumor progression.

AB - Heightened secretion of protumorigenic effector proteins is a feature of malignant cells. Yet, the molecular underpinnings and therapeutic implications of this feature remain unclear. Here, we identify a chromosome 1q region that is frequently amplified in diverse cancer types and encodes multiple regulators of secretory vesicle biogenesis and trafficking, including the Golgi-dedicated enzyme phosphatidylinositol (PI)-4-kinase IIIβ (PI4KIIIβ). Molecular, biochemical, and cell biological studies show that PI4KIIIβ-derived PI-4-phosphate (PI4P) synthesis enhances secretion and accelerates lung adenocarcinoma progression by activating Golgi phosphoprotein 3 (GOLPH3)-dependent vesicular release from the Golgi. PI4KIIIβ-dependent secreted factors maintain 1q-amplified cancer cell survival and influence prometastatic processes in the tumor microenvironment. Disruption of this functional circuitry in 1q-amplified cancer cells with selective PI4KIIIβ antagonists induces apoptosis and suppresses tumor growth and metastasis. These results support a model in which chromosome 1q amplifications create a dependency on PI4KIIIβ-dependent secretion for cancer cell survival and tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=85078307256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078307256&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aax3772

DO - 10.1126/scitranslmed.aax3772

M3 - Article

C2 - 31969487

AN - SCOPUS:85078307256

VL - 12

IS - 527

M1 - eaax3772

ER -

PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this